TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01159418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589), Carboplatin and Paclitaxel
Description: 1. Panobinostat (LBH589) p.o. on days 1,4,8 and 11 of each cycle (20mg-45mg).Carboplatin i.v.on day 1 at a total dose corresponding to a AUC of 5 µg/ml.h. Paclitaxel as 3 hour infusion on day 1 (135 mg/m2).~2. Panobinostat (LBH589) p.o. on days 1, 4, 15 and 18 of each cycle (20mg-30mg).Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175mg/m2).~3. Once the MTD is achieved:Panobinostat (LBH589) p.o. on days 1 and 4 of each cycle(20mg-30 mg). Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175 mg/m2).~The treatment will be repeated every three weeks until disease progression.
Study: NCT03265028

Intervention type: BEHAVIORAL
Intervention: TRACE e-learning
Description: The TRACE e-learning (www.acutecough.org) is an educational web-based module including communication training for physicians, and includes patient booklets to be used interactively during the consultation.
Study: NCT02591017

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Chitosan
Study: NCT01591681

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pump suspension
Description: The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
Study: NCT02591017

Intervention type: DRUG
Group type: OTHER
Intervention: Chitosan
Study: NCT01788163

Intervention type: GENETIC
Group type: OTHER
Intervention: EGFR mutation test
Description: EGFR mutation being tested in tissue and blood
Study: NCT04720573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: 50 mcg/kg neostigmine was used under the guidance of TOF monitoring after cessation of anesthesia.
Study: NCT01258205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 139
Description: Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).
Study: NCT04720573

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: 2 mg/kg sugammadex was used under the guidance of TOF monitoring after cessation of anesthesia.
Study: NCT01723904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Application of Rotigotine up to 8 mg/24 h patches for 24 hours.
Study: NCT05977595

Intervention type: OTHER
Intervention: Quick DASH Score Visual Analog Scale Scar quality Healing Number of surgeries
Description: Functional and aesthetic criteria : Quick DASH Score at 3 month and 6 months, Visual Analog Scale at 3 month and 6 months, scar quality (assessment by surgeon), healing (discontinuation of dressings), need for a second surgical procedure.
Study: NCT04072965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance training
Description: Thirty five females with CAI will be recruited from the Faculty of Physical Therapy, Cairo University by announcements to participate in this study. The participants will be randomly assigned into three groups; (A) Cross Education will receive single leg balance training for the non affected side (n=10), (B) Traditional training will receive single leg balance training for the affected side (n=10), (C) control group will receive no intervention (n=15).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance training
Description: Thirty five females with CAI will be recruited from the Faculty of Physical Therapy, Cairo University by announcements to participate in this study. The participants will be randomly assigned into three groups; (A) Cross Education will receive single leg balance training for the non affected side (n=10), (B) Traditional training will receive single leg balance training for the affected side (n=10), (C) control group will receive no intervention (n=15).
Study: NCT02149589

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mechanical ventilation
Study: NCT03985813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening Wizard
Description: Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
Study: NCT03783559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy±target therapy
Description: chemotherapy±target therapy
Study: NCT00402779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet by mouth daily
Study: NCT02494583

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 80 mg/m\^2 IV on Day 1 of each week in 3-week cycles (6 cycle maximum per local country guidelines).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 80 mg/m\^2 IV on Day 1 of each week in 3-week cycles (6 cycle maximum per local country guidelines).
Study: NCT03783559

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy±target therapy
Description: chemotherapy±target therapy
Study: NCT02494583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 800 mg/m\^2/day IV continuous from Day 1-5 of each 3-week cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-FU
Description: 5-FU 800 mg/m\^2/day IV continuous from Day 1-5 of each 3-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2 twice daily by oral tablet on Day 1-14 of each 3-week cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2 twice daily by oral tablet on Day 1-14 of each 3-week cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
Study: NCT00797316

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Aliskiren 150 mg or 300 mg taken once daily in oral form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg or 300 mg taken once daily in oral form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 mg or 25 mg taken once daily in oral form.
Study: NCT04975113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive neuromuscular exercise program
Description: The exercises to be performed in the following week at the beginning of each week were explained by the researcher physiotherapist on the brochure and given as a home program and continued for a total of 12 weeks. The researcher physiotherapist saw the patients every week and carried out exercise compliance and control.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and Taping
Description: I taping for accurate positioning of the tissue was applied to the patients to neutralize the patellofemoral joint. During the knee flexion in the supine position, the tape was adhered to the skin with a moderate-to-extreme stretch (50%-75%) . Clinical therapeutic applications of the Kinesio taping methods (Tokyo, Japan: Ken Ikai Co Ltd.). In addition to the patellar taping, correction taping to neutralize the subtalar joint by elevating the midtarsal joint and medial arch was applied. The patients were positioned in prone lying and knee flexion position, the taping was started at the 5th metatarsal level on the dorsal side of the finger and finished extending towards the medial of the tibia . Tapings were renewed at the beginning of each week for 6 weeks.
Study: NCT01739465

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Description: Photodynamic therapy
Study: NCT01016158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical cord serum eyedrops
Description: 20% umbilical cord serum eye drops 3 to 4 times a day
Study: NCT01892020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 50
Description: Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 50
Description: Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
Study: NCT00486577

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: significant chronic primary auditory cortex stimulation during the first two weeks
Description: significant chronic primary auditory cortex stimulation during the first two weeks of the follow up than wash out period followed by two weeks of non significant stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non significant chronic primary auditory cortex stimulation during the first two weeks
Description: non significant stimulation during the first two weeks of the follow up than wash out period followed by two weeks of significant chronic primary auditory cortex stimulation
Study: NCT02270060

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Listening
Description: Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
Study: NCT02752451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Anatomic Arthroscopy Simulation
Description: Knee arthroscopy training using Cigar Box Arthroscopy Trainer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anatomic Arthroscopy Simulation
Description: Knee arthroscopy training using Anatomic Knee Arthroscopy Trainer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-assesment education
Description: Reading material and lecture with only still images about performing diagnostic knee arthroscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-assesment education
Description: Reading material and lecture with only still images about performing diagnostic knee arthroscopy

Intervention type: OTHER
Group type: OTHER
Intervention: Pre-assesment education
Description: Reading material and lecture with only still images about performing diagnostic knee arthroscopy
Study: NCT01669343

Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period. Part B In overweight/obese participants who completed Part A, provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period.
Study: NCT02323594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Treatment A= single oral dose of Daclatasvir (DCV) tablet and Treatment B= single oral dose of DCV pediatric chewable tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Treatment C= single oral dose of Daclatasvir (DCV) pediatric chewable tablet and Treatment D= single oral dose of DCV pediatric chewable tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir
Description: Treatment E= single oral dose of Asunaprevir (ASV) tablet and Treatment F= single oral dose of ASV pediatric chewable tablet and Treatment G= single oral dose of of ASV pediatric chewable tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Treatment H= single oral dose of Daclatasvir (DCV) tablet and Treatment I= single oral dose of DCV tablets
Study: NCT04509531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wise Intervention (SA, ITP and resilience)
Description: The intervention will be based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. This will include activities such as reading scientific information about social behavior and its role in people's well-being and mental health, the meaning of online victimization experiences and ways to react to them, experiences of other young people of their age, and self-persuasion exercises that involve an active commitment to change. Furthermore, it provides a number of strategies to manage everyday conflicts among adolescents. This intervention teaches them new ways to manage these difficulties through different actions (relaxation, distraction, sports, etc.). Finally, they are asked to plan the strategies they will use in the future in the face of some difficulties and to recommend some guidelines for another adolescent who may be going through a similar situation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard preventive intervention
Description: The control intervention will involve scientific information and education about internet risks such as sexting and grooming.
Study: NCT03699306

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NG tube insertion method
Description: a feeding tube called naso-gastric or NG tube were inserted through nostril inside the stomach randomly by one of three methods mentioned earlier

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NG tube insertion method
Description: a feeding tube called naso-gastric or NG tube were inserted through nostril inside the stomach randomly by one of three methods mentioned earlier

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NG tube insertion method
Description: a feeding tube called naso-gastric or NG tube were inserted through nostril inside the stomach randomly by one of three methods mentioned earlier
Study: NCT03498534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid 300Mg Tab
Description: -TST tests will receive isoniazid 300Mg Tab for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid 300 MG
Description: + TST test will receive isoniazid 300MG Tab for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid 300 MG
Description: HIV positive patient will receive isoniazid 300MGTab for 6 months
Study: NCT03920514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: Women will be given hCG before or with IUI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: Women will be given hCG before or with IUI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: Women will be given hCG before or with IUI
Study: NCT03855189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate (MF)
Description: Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone Dipropionate (BDP)
Description: Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) \[336 mcg total dose per day\] for 4 weeks.
Study: NCT04000529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: Capsule
Study: NCT03855189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo nasal spray administered for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray administered for 4 weeks.
Study: NCT01687517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine available for the 2012-2013 vaccine campaign
Description: Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal influenza vaccine available for the 2012-2013 vaccine campaign
Description: Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)
Study: NCT02455986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The StepSmart Challenge
Description: A six month pedometer based intervention designed to increase Physical Activity in school children
Study: NCT04000529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Concentrate for solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Capsule and tablet
Study: NCT03402945

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prevena
Description: Negative-Pressure Wound Management System
Study: NCT03495024

Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline
Description: Oral medication approved to facilitate smoking cessation
Study: NCT02885233

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Free From Falls Online
Description: Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist Control
Description: Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion.
Study: NCT00574860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3285
Description: Oral rinse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral rinse

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: This will be the therapy most commonly used the the institution treating the patient
Study: NCT01713595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline Aerosol
Description: A single 5ml dose of 7% Saline aerosol
Study: NCT03933293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK102
Description: 450mg, Q4W, subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins
Description: Lipid-lowering therapies

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statins
Description: Lipid-lowering therapies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Lipid-lowering therapies
Study: NCT03402945

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prevena
Description: Negative-Pressure Wound Management System

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: antibiotic
Study: NCT03933293

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ezetimibe
Description: Lipid-lowering therapies
Study: NCT04181710

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Kidney transplant
Description: Organ preserved in preservation solution

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplant
Description: Organ preserved in preservation solution
Study: NCT03402945

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Description: antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: antibiotic
Study: NCT03920514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: Women will be given hCG before or with IUI
Study: NCT03036826

Intervention type: DRUG
Intervention: Piperacillin/tazobactam
Description: antiinfective therapy with Piperacillin/Tazobactam within routine care

Intervention type: DRUG
Intervention: Meropenem
Description: antiinfective therapy with Meropenem within routine care
Study: NCT03402945

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard wound dressing
Description: Any non-negative pressure wound dressing that is routinely used at study sites will be considered standard of care in the control arms.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard wound dressing
Description: Any non-negative pressure wound dressing that is routinely used at study sites will be considered standard of care in the control arms.
Study: NCT03764592

Intervention type: OTHER
Intervention: radiofrequency ablation
Description: Symptomatic patients whose substrates were identified will undergo catheter ablation; asymptomatic patients will be followed without undergoing catheter ablation.
Study: NCT03397511

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Description: Baseline Interview, 2 Counseling Sessions at baseline and 2 weeks post baseline, and one follow up survey at one month